Zomedica SVP buys 216,899 shares of stock

Zomedica Corp. reports that Sr.

Rhea-AI Filing Summary

Zomedica Corp. reports that Sr. Vice President, Sales, Russell Kevin Klass purchased an aggregate 216,899 shares of common stock, without par value, in three open-market transactions at prices between $0.1050 and $0.1070 per share. Following these purchases, he directly holds 6,001,000 common shares.

Insider Trade Summary

Net Buyer: 216,899 shares

Net Buy 3 txns

Insider Klass Russell Kevin

Role Insider

Bought 216,899 shs ($23K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, without par value	200,000	$0.105	$21K
Purchase	Common Stock, without par value	11,399	$0.107	$1K
Purchase	Common Stock, without par value	5,500	$0.105	$577.50

Holdings After Transaction: Common Stock, without par value — 6,001,000 shares (Direct)

Key Figures

Shares purchased: 216,899 shares Purchase price: $0.1050 per share Purchase price: $0.1070 per share +2 more

5 metrics

Shares purchased 216,899 shares Aggregate common stock purchased in the reported transactions

Purchase price $0.1050 per share Price on the 200,000-share and 5,500-share purchases

Purchase price $0.1070 per share Price on the 11,399-share purchase

Post-transaction holdings 6,001,000 shares Direct common stock held after the reported purchases

Number of purchase transactions 3 transactions Count of non-derivative open-market or private purchase entries

Key Terms

Common Stock, without par value, Purchase in open market or private transaction, Rule 10b5-1

3 terms

Common Stock, without par value financial

"security_title 'Common Stock, without par value'"

Purchase in open market or private transaction financial

"transaction_code_description 'Purchase in open market or private transaction'"

Rule 10b5-1 regulatory

"aff_10b5_one field related to 'Rule 10b5-1' trading plans"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ZOMDF disclose in this Form 4?

Zomedica disclosed that Sr. Vice President, Sales, Russell Kevin Klass purchased 216,899 common shares in three open-market transactions at prices between $0.1050 and $0.1070 per share, increasing his direct ownership position.

How many Zomedica (ZOMDF) shares did Russell Kevin Klass buy?

Russell Kevin Klass bought a total of 216,899 Zomedica common shares. The purchases were split into blocks of 200,000, 11,399, and 5,500 shares, all reported as open-market or private transactions.

What prices did the ZOMDF insider pay for the purchased shares?

The insider paid $0.1050 per share for two of the transactions and $0.1070 per share for the remaining transaction. All three were reported as purchases in open-market or private transactions of common stock without par value.

How many Zomedica (ZOMDF) shares does Russell Kevin Klass own after these trades?

After the reported purchases, Russell Kevin Klass directly holds 6,001,000 Zomedica common shares. This post-transaction holding reflects his direct ownership position as reported in the filing’s canonical holdings data.

Were the ZOMDF insider purchases made under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox for this filing is not marked as affirming a trading plan. That indicates the purchases were not reported as being made pursuant to a Rule 10b5-1 pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klass Russell Kevin

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE.

STE 100.

(Street)

ANN ARBOR. MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Sr. Vice President, Sales

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	05/20/2026		P		200,000	A	$0.105	5,984,101	D
Common Stock, without par value	05/21/2026		P		11,399	A	$0.107	5,995,500	D
Common Stock, without par value	05/21/2026		P		5,500	A	$0.105	6,001,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Kevin Klass	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)